SCHEDULE: Affinity Asset Advisors Discloses 9.99% Stake in iBio

Sentiment:

Beneficial Ownership Disclosure 29 January 2026 9:29 PM

Affinity Asset Advisors, LLC and Michael Cho have disclosed a 9.99% beneficial ownership stake in iBio, Inc., including shares from warrants and a recent private placement.

Capital raiseThe filing references 1,408,481 shares of Common Stock issued in connection with a private placement that closed on or about January 13, 2026.This private placement was reported in the Issuer's Form 8-K filed with the SEC on January 12, 2026.

Summary

Affinity Asset Advisors, LLC and Michael Cho have reported a beneficial ownership of 2,401,616 shares of iBio, Inc. common stock.
This represents approximately 9.99% of iBio, Inc.'s outstanding common stock.
The reported ownership includes 144,416 shares issuable upon the exercise of warrants, which are subject to a 9.99% beneficial ownership limitation.
The calculation of the percentage is based on 24,040,205 shares of common stock outstanding, which includes shares from a private placement that closed around January 13, 2026.
Affinity Asset Advisors, LLC, as the investment manager of Affinity Healthcare Fund, LP, and Michael Cho, as its managing member, exercise sole voting and dispositive power over these shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by an investment advisor suggests a vote of confidence in iBio, Inc.'s equity, potentially indicating perceived value or future growth prospects.

Positives

A significant stake (9.99%) by an institutional investor like Affinity Asset Advisors, LLC, and its managing member Michael Cho, could signal confidence in iBio, Inc.'s future prospects.
The acquisition of shares, including through a recent private placement, indicates active investment in the company.

Negatives

Risks

Future Outlook

Industry Context

StockSavvy.ai notes that significant institutional ownership disclosures, such as this 9.99% stake by Affinity Asset Advisors, are common in the biotechnology and pharmaceutical sectors, where specialized funds often take positions in companies with promising pipelines or technologies. This type of filing primarily signals an investor's belief in the long-term value proposition rather than immediate operational changes.

Stakeholder Impact

Shareholders: The disclosure of a significant institutional investor taking a nearly 10% stake could be viewed positively, potentially increasing investor confidence and demand for the stock.
Company Management: A large institutional holder may exert influence on corporate strategy or governance, though the filing states the shares were not acquired for changing or influencing control.

Key Dates

Date	Description
2025-11-10	Date of 22,487,308 shares of Common Stock outstanding as reported in Issuer's Form 10-Q/A.
2025-11-17	Date Issuer's Form 10-Q/A was filed with the SEC.
2026-01-12	Date Issuer's Form 8-K was filed with the SEC reporting a private placement.
2026-01-13	Approximate closing date of a private placement where 1,408,481 shares of Common Stock were issued.
2026-01-22	Date of event which requires filing of this statement (beneficial ownership threshold reached).
2026-01-29	Date of signing and filing of the Schedule 13G Amendment No. 2.

Recommendation

hold

This filing primarily discloses a significant beneficial ownership stake by an investment advisor. While a large institutional stake can be a positive signal of confidence, the filing itself does not provide new operational or financial data to warrant a "buy" or "sell" recommendation. It's a disclosure of an existing position and a past capital raise, suggesting a "hold" until further operational or financial updates from iBio, Inc. are available.

Keywords

iBio Inc, Affinity Asset Advisors, Michael Cho, Schedule 13G, beneficial ownership, common stock, investment advisor, institutional ownership, equity stake, warrants, private placement

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.